We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Aptose Biosciences Inc (APS) NPV

Sell:2.30 CAD Buy:2.60 CAD Change: 0.04 CAD (1.58%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Sell:2.30 CAD
Buy:2.60 CAD
Change: 0.04 CAD (1.58%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Sell:2.30 CAD
Buy:2.60 CAD
Change: 0.04 CAD (1.58%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Contact details

Address:
251 Consumers Rd Suite 1105
NORTH YORK
M2J 4R3
Canada
Telephone:
+1 (647) 4799828
Website:
https://aptose.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APS
ISIN:
CA03835T3091
Market cap:
31.39 million CAD
Shares in issue:
12.86 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • William Rice
    Chairman of the Board, President, Chief Executive Officer
  • Fletcher Payne
    Chief Financial Officer, Senior Vice President, Chief Business Officer
  • Rafael Bejar
    Senior Vice President, Chief Medical Officer
  • Philippe Ledru
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.